EQL PHARMA AB Cash Flow-to-Debt Ratio
EQL PHARMA AB cash flow-to-debt ratio. EQL PHARMA AB (7JK) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of €16.79 Million could theoretically repay 0% of its total liabilities (€583.83 Million) in one year. Check total reinvestment intensity of EQL PHARMA AB to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of EQL PHARMA AB (2022–2026)
Cash flow-to-debt ratio of EQL PHARMA AB from 2022 to 2026. Historical debt coverage capacity for EQL PHARMA AB across 5 annual periods. Check EQL PHARMA AB (7JK) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
EQL PHARMA AB Cash Flow-to-Debt Ratio by Year (2022–2026)
EQL PHARMA AB cash flow-to-debt ratio by year from 2022 to 2026. Year-by-year debt coverage analysis for EQL PHARMA AB. For the full cash flow conversion analysis, see EQL PHARMA AB (7JK) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.05x | €28.36 Million | €583.83 Million | ▲ +215.8% |
| 2025 | -0.04x | €-24.65 Million | €587.79 Million | ▲ +28.1% |
| 2024 | -0.06x | €-11.44 Million | €196.03 Million | ▼ -127.7% |
| 2023 | 0.21x | €27.62 Million | €130.94 Million | ▼ -42.4% |
| 2022 | 0.37x | €41.83 Million | €114.26 Million | — |